Literature DB >> 2973580

[Sensitivity of Pseudomonas aeruginosa and Klebsiella spp. to ceftazidime. Current status in France].

A Thabaut1, J Acar, G Arlet, L Berardi-Grassias, E Bergogne-Bérézin, Y Brun, Y Buisson, G Chabanon, R Cluzel, A Courtieu.   

Abstract

Ceftazidime was tested against 2,224 strains of Pseudomonas aeruginosa obtained from 17 hospitals in April, May and June, 1986 and against 607 strains of Klebsiella pneumoniae and 234 strains of K. oxytoca obtained from 16 hospitals in October, 1987. The MIC's of ceftazidime against P. aeruginosa were distributed normally, with an MIC50 of 2 mg/l and an MIC90 of 4 mg/l. Depending on critical concentrations, 80 per cent of strains were sensitive, 11.4 per cent were of intermediate sensitivity and 0.54 per cent were resistant. There were few differences in results between hospitals. Ninety-two per cent of resistant strains and 45 per cent of intermediate strains (as opposed to 6 per cent of all strains) produced a high-level constitutive cephalosporinase with little variations between centres. The MIC's of ceftazidime against K. pneumoniae and K. oxytoca had a bimodal distribution: 91 per cent of strains were sensitive to 0.25 mg/l, 6 per cent of strains showed intermediate sensitivity and 3 per cent were resistant. All intermediate and resistant strains produced a very broad spectrum beta-lactamase which hydrolyzed some of the third generation cephalosporins: K. pneumoniae 36 CTX-1, 5 SHV-2, and 14 strains producing a recently identified beta-lactamase "CAZ-5/SHV-4"; K. oxytoca 3 CTX-1. These strains were isolated in 10 of the 16 hospitals which took part in the 1987 study. Comparison of these results with those of studies performed in 1984 and 1985 showed a moderate increase in the number of intermediate sensitivity strains of P. aeruginosa and the occasional occurrence, of the epidemic type, in some hospitals of Klebsiella spp. producing very broad spectrum beta-lactamases which were rare in 1985.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2973580

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  5 in total

1.  Epidemiology of extended spectrum beta-lactamases.

Authors:  A Philippon; S Ben Redjeb; G Fournier; A Ben Hassen
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

Review 2.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

3.  Perspectives of beta-lactamases inhibitors in therapy of infections caused by Escherichia coli or Klebsiella with plasmidic resistance to third generation cephalosporins.

Authors:  A Bauernfeind
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

4.  A new plasmidic cefotaximase in a clinical isolate of Escherichia coli.

Authors:  A Bauernfeind; H Grimm; S Schweighart
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

5.  TEM-4, a new plasmid-mediated beta-lactamase that hydrolyzes broad-spectrum cephalosporins in a clinical isolate of Escherichia coli.

Authors:  G C Paul; G Gerbaud; A Bure; A M Philippon; B Pangon; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.